Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)-Reference-Cited by-同舟云学术

Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)

Published:2020-05-02 Issue:2 Volume:31 Page:119-131
ISSN:1046-3976
Container-title:Endocrine Pathology
language:en
Short-container-title:Endocr Pathol

Author:

Schiavo Lena Marco,Partelli Stefano,Castelli Paola,Andreasi Valentina,Smart Chanel Elisha,Pisa Eleonora,Bartolomei Mirco,Bertani Emilio,Zamboni Giuseppe,Falconi Massimo,Doglioni Claudio

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12022-020-09623-4.pdf

Reference41 articles.

1. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016. DOI: https://doi.org/10.1159/000443171

2. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017. DOI: https://doi.org/10.1159/000471880

3. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 2017. DOI: https://doi.org/10.1159/000473892

4. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. European Journal of Nuclear Medicine and Molecular Imaging 2003 DOI: https://doi.org/10.1007/s00259-002-1023-y

5. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 2008 May;26(13):2124–30.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study;British Journal of Surgery;2024-08-30

2. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review;Chinese Clinical Oncology;2024-04

3. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis;Journal of Cancer Research and Therapeutics;2024-04

4. Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

5. Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms;Endocrine;2023-10-16